Michael Rome, Ph.D.

Dr. Rome joined Foresite Capital in 2016 and, as Managing Director, leads the therapeutics investing practice. Michael has led numerous investments including: XinThera (acquired by Gilead Sciences), Affinivax (acquired by GSK), Turning Point Therapeutics (acquired by BMS), Pharvaris (Nasdaq: PHVS), Nurix (Nasdaq: NRIX), CG Oncology (Nasdaq: CGON), and Alumis where he led the acquisition of […]

Vishal Deshmukh, PhD

Vishal Deshmukh, PhD is a biopharmaceutical scientist and investor with rich expertise spanning early discovery through clinical development across multiple therapeutic areas. He is recognized for his leadership in advancing small-molecule and biologics programs in oncology and other serious diseases. Vishal is a member of the investment team at Foresite Capital, focused on biotechnology investments. […]

white logo.